TOP - May 2019, Vol 12, No 2
By Wayne Kuznar
The discontinuation of a tyrosine kinase inhibitor (TKI) is considered safe and appropriate in consenting patients with chronic-phase chronic myeloid leukemia (CML) under specific circumstances and with careful molecular monitoring, according to the updated National Comprehensive Cancer Network (NCCN) management guideline for CML.
By Phoebe Starr
The adjuvant use of the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1; Kadcyla) led to a clinically meaningful and statistically significant improvement in invasive disease-free survival.
The May issue of The Oncology Pharmacist (TOP) features presentations from national and international meetings, including the 2019 Hematology/Oncology Pharmacy Association (HOPA) Conference, the National Comprehensive Cancer Network (NCCN) 2019 Conference, the 2019 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium, and the 2019 Genitourinary Cancers Symposium.